The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Open accessAbstract
BACKGROUND: Familial hypercholesterolemia is characterized by an elevated level of low-density lipoprotein (LDL) cholesterol and an increased risk of premature atherosclerotic cardiovascular disease. Monoclonal antibodies directed against proprotein convertase subtilisin-kexin type 9 (PCSK9) have been shown to reduce LDL cholesterol levels by more than 50% but require administration every 2 to 4 weeks. In a phase 2 trial, a twice-yearly injection of inclisiran, a small interfering RNA, was shown to inhibit hepatic synthesis of PCSK9 in adults with heterozygous familial hypercholesterolemia. METHODS: In this phase 3, double-blind trial, we randomly assigned, in a 1:1 ratio, 482 adults who had heterozygous familial hypercholesterolemia to receive subcutaneous injections of inclisiran sodium (at a dose of 300 mg) or matching placebo on days 1, 90, 270, and 450. The two primary end points were the percent change from baseline in the LDL cholesterol level on day 510 and the time-adjusted percent change from baseline in the LDL cholesterol level between day 90 and day 540. RESULTS: The median age of the patients was 56 years, and 47% were men; the mean baseline level of LDL cholesterol was 153 mg per deciliter. At day 510, the percent change in the LDL cholesterol level was a reduction of 39.7% (95% confidence interval [CI], -43.7 to -35.7) in the inclisiran group and an increase of 8.2% (95% CI, 4.3 to 12.2) in the placebo group, for a between-group difference of -47.9 percentage points (95% CI, -53.5 to -42.3; P<0.001). The time-averaged percent change in the LDL cholesterol level between day 90 and day 540 was a reduction of 38.1% (95% CI, -41.1 to -35.1) in the inclisiran group and an increase of 6.2% (95% CI, 3.3 to 9.2) in the placebo group, for a between-group difference of -44.3 percentage points (95% CI, -48.5 to -40.1; P<0.001). There were robust reductions in LDL cholesterol levels in all genotypes of familial hypercholesterolemia. Adverse events and serious adverse events were similar in the two groups. CONCLUSIONS: Among adults with heterozygous familial hypercholesterolemia, those who received inclisiran had significantly lower levels of LDL cholesterol than those who received placebo, with an infrequent dosing regimen and an acceptable safety profile. (Funded by the Medicines Company; ORION-9 ClinicalTrials.gov number, NCT03397121.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inclisiran lowered LDL-C by 47.9% in the 482 HeFH patients enrolled in ORION-9 at Day 510 [39].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The analysis of 11 RCTs for quantitative synthesis included more than 13,000 participants showed inclisiran produces significant LDL-C reduction versus placebo treatment [24, 25, 38–44, 46, 49].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The study by Raal et al. focused on HeFH patients displayed an outlier position in the lower left quadrant of the funnel because it had both a small effect size and a wide standard error [39].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [39]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These results were confirmed in the phase 3 ORION-9 trial which showed a − 48% LDL-C reduction of inclisiran relative to placebo among 482 patients with HeFH [138].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [138]
The cited source says what the claim attributes to it.
In the citing paper
“Inclisiran improved multiple lipid parameters including non-HDL-C, apoB, triglycerides and lipoprotein(a) in addition to LDL-C which makes it beneficial for complete lipid management [39, 43, 49].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Heart Disease and Stroke Statistics—2014 Update
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2013) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,264
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationSequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., Wiklund, O., Hegele, R. A., Raal, F. J., Defesche, J. C., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht273 · Cited by 2,761
Self-citationEfficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Self-citationTherapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charissé, K., Constien, R., Donoghue, M., Elbashir, S. M., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,206
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 820
Real-World Efficacy of Inclisiran in Veneto Region (Italy): The INCLIVEN Multicenter Registry
Briani, F., Sani, E., Venturi, G., Bacchion, F., Balzano, S., Battocchio, M., D'Elia, K., Frigo, G. M., Licchelli, L., Lupo, A., et al. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07749-3 · Cited by 6
Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know
Parham, J. S., & Goldberg, A. C. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01036-4 · Cited by 5
Chaudhry, T., Coxon, C. R., & Ross, K. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.08.005 · Cited by 5
Daman, K., Yan, J., Biscans, A., Echeverria, D., Shmushkovich, T., Wolfson, A. D., Alterman, J. F., Khvorova, A., & Emerson, C. P. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101513 · Cited by 4
Engineering chimeric PCSK9 for a vaccine against atherosclerosis
Malenšek, Š., Lainšček, D., Esih, H., Orehek, S., Fink, T., Golob-Urbanc, A., Blinc, A., & Jerala, R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101535 · Cited by 4
Bharaj, I. S., Purewal, K., Munaim, J., Brar, A. S., Kacheria, A., Simister, A., Thirupathy, U., Gupta, P., Kahlon, J., Thwe, E. E., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13092192 · Cited by 4
Kennett, A. M. R., Lie, L., Flerin, M., Kurt, B. Z., Baker, Y. R., Hill, A. C., Ramesh, A., Wood, M. J. A., Dhara, D., El-Sagheer, A. H., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202511386 · Cited by 4
Dysregulated Lipid Metabolism as a Central Driver of Atherosclerotic Plaque Pathology
Steinbeck, J. E., Iannotti, R. A., & Rasheed, A. (2025) · Lipidology · doi:10.3390/lipidology2040017 · Cited by 5
Azari, S., Pourasghari, H., Rezaei, M. A., Behzadifar, M., Salehbeigi, S., Rajaei, S., Jafarzadeh, D., Soleimanpour, S., & Tajdini, M. (2025) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-025-00671-3 · Cited by 6
Ballantyne, C. M., Graham, T. E., Anglen, L. J. V., Iteld, B. J., Serota, H., Niu, X., McElligott, S. C., Hanna, K. E., & Varisco, T. J. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00438-0 · Cited by 4
A Photoelectrocatalytic Platform for Sequence‐Unrestricted Modification of Oligonucleotide Backbones
Yuan, K., Zhuang, H. J., Jiang, Y., Cai, Y., Xu, B., & Shang, M. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202524814 · Cited by 4
Nucleic Acid–Based Therapies — The Next Frontier in Treating Dyslipidemias
Hegele, R. A. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.01.026 · Cited by 4
Qiu, Z., Wang, R.-Y., Zhang, Y., Huang, H.-B., He, R.-Y., Yan, H., Luo, P., Yang, B., Xu, Z.-F., & He, Q.-J. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01729-x · Cited by 6
Therapeutic siRNA: Mechanisms, challenges, strategies, and clinical translation
Jiang, Q., Fu, J., An, Y., & Liu, Y. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004061 · Cited by 4
Nucleic Acid Therapy for the Skin
Chai, A. C., Siegwart, D. J., & Wang, R. C. (2024) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2024.07.029 · Cited by 4
Taha, H., Kandil, H., Badran, H. M., Farag, N. M., Khamis, H., Nasr, G. M., Samy, M., Abdrabou, M., Abuelezz, M., & Shaker, M. M. (2024) · The Egyptian Heart Journal · doi:10.1186/s43044-024-00562-7 · Cited by 5
Synthesis of New Polyfluoro Oligonucleotides via Staudinger Reaction
Klabenkova, K., Zakhryamina, A., Burakova, E. A., Bizyaev, S. N., Фокина, А. А., & Stetsenko, D. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010300 · Cited by 4
Gagnon, É., Gill, D., Bourgault, J., Gobeil, É., Mitchell, P. L., Girard, A. S., Paulin, A., Couture, C., Bossé, Y., Thériault, S., et al. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf078 · Cited by 3
Self-citationDodulík, J., Plášek, J., Kacířová, I., Uřinovská, R., Vrtal, J., & Václavík, J. (2025) · Pharmaceuticals · doi:10.3390/ph18060818 · Cited by 4
CMC and regulatory aspects of oligonucleotide therapeutics
Rupp, T. M., & Cramer, H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821595-1.00012-9 · Cited by 4
Current and emerging drugs for the treatment of atherosclerosis: the evidence to date
Rizvi, A. A., Popovic, D. S., Παπάνας, Ν., Stoian, A. P., Almahmeed, W. A., Sahebkar, A., Janež, A., & Rizzo, M. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2094771 · Cited by 4
Tsamoulis, D., Rallidis, L. S., & Kosmas, C. E. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2360415 · Cited by 4
Ganjali, S., Cardenia, V., Bonciolini, A., Santos, R. D., Al‐Rasadi, K., & Sahebkar, A. (2024) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2024.110812 · Cited by 4
Movahedan, M., Ellis, U. M., & Barry, A. R. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00682-0 · Cited by 4
Li, H., Zhao, S., Wu, J., Han, J., Xu, Y., Shi, S., & Zhang, Y. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02294-8 · Cited by 5
The era of targeted therapy for hyperlipidemia
Чубыкина, У. В., Tyurina, A. V., & Владиславович, Е. М. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6038 · Cited by 6
Bettinsoli, V., Melzi, G., Crea, A., Esposti, L. D., Iafisco, M., Catalucci, D., Ciana, P., & Corsini, E. (2025) · Life · doi:10.3390/life15010095 · Cited by 4
Efficacy, benefit and safety of inclisiran
López-Miranda, J. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.100730 · Cited by 4
Vecchia, L. A. D., STEFANO, F. D., Bussotti, M., Godino, C., Bernardi, M., Spadafora, L., Adriano, E. P., Guarini, P., & Pedretti, R. F. E. (2025) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.25.06704-3 · Cited by 4
2024 KSoLA Update on New Lipid-Lowering Agents: Inclisiran and Bempedoic Acid
Kim, H., Cha, J., & Lee, S. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.2.135 · Cited by 6
Small interfering RNA (siRNA) in dyslipidemia: a systematic review on safety and efficacy of siRNA
Alla, S. S. M., Shah, D. J., Meyur, S., Agarwal, P., Alla, D., Moraboina, S. L., Ghadvaje, G. V., Bayeh, R. G., Malireddi, A., Shajan, T., et al. (2025) · Journal of Experimental Pharmacology · doi:10.2147/jep.s521579 · Cited by 4
Hubaud, A., & Singh, A. P. (2021) · Trends in Genetics · doi:10.1016/j.tig.2021.04.001 · Cited by 4
McIntosh, C. S., Watts, G., Wilton, S., & Aung-Htut, M. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000793 · Cited by 3
Innovative lipid-lowering therapy: experience of inclisiran use in the Republic of Belarus
Medvedeva, E. A., Григоренко, Е. А., & Mitkovskaya, N. P. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5417 · Cited by 4
An update on emerging drugs for the treatment of hypercholesterolemia
Nelson, A. J., Bubb, K. J., & Nicholls, S. J. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.2009801 · Cited by 4
Co-repressing immunometabolic processes in atherosclerosis
Stein, S. (2022) · Cardiovascular Medicine · doi:10.4414/cvm.2021.02142 · Cited by 4
Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations
Stürzebecher, P. E., & Laufs, U. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000935 · Cited by 3
Lipoprotein(a) and aortic stenosis: Practical insights
Dimitriadis, K. S., Kyriakoulis, K. G., Pyrpyris, N., Beneki, E., Kamperidis, V., Κόλλιας, Α., Cenko, E., Aznaouridis, K. A., Aggeli, K. D., & Tsioufis, K. P. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104124 · Cited by 3
Non coding RNA biomarkers in pemphigus disease
Li, Z., Huang, J., Zhang, S. Y., Zhang, W., & Si, X. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120381 · Cited by 4
Grogan, M. A., Sheikh, F. H., Sperry, B. W., Sweetser, M. T., Capocelli, K., Roblin, S., & Witteles, R. M. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102590 · Cited by 4
Choi, J., & Gwon, J. (2025) · Vascular Specialist International · doi:10.5758/vsi.250043 · Cited by 5
Jaiswal, V., Goyal, A., Deb, N., Shama, N., Mittal, V., Rajak, K., Halder, A., Khadka, S., Kumar, T., Ahmed, R., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101311 · Cited by 3
Lupi, A., Baluci, M., Persampieri, S., Perversi, I., Presutti, D. G., Somaschini, A., Gaudio, G. V., Guasti, L., Ferrini, M., Corsini, A., et al. (2025) · Atherosclerosis Plus · doi:10.1016/j.athplu.2025.09.005 · Cited by 3
Lipoprotein(a) Lowering with Pelacarsen (TQJ230)
Sharma, K., Kattamuri, L. P. V., & Mukherjee, D. (2025) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x399029250923100015 · Cited by 4
Lipid lowering therapies in chronic kidney disease: A call to action
Ruiz, J. M., Arroyo, D., de Cos, M., Fernández, M. R., Sánchez-Álvarez, E., Bores, P. G., Hernández, J. L., & Corral, P. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120563 · Cited by 4
Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation
Oshima, A., Serruys, P. W. J. C., Garg, S., McEvoy, J. W., Wood, D. A., Doenst, T., Taggart, D. P., Puskas, J. D., Shajahan, A., Sharif, F., et al. (2026) · EuroIntervention · doi:10.4244/eij-d-25-00598 · Cited by 4
Self-citationZhang, X., Wang, Y., Miao, X., Guan, R., & Li, H. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.174719 · Cited by 3
Knowlton, K. U., Návar, A. M., Anderson, J. L., Brown, A. S., Muhlestein, J. B., Kleeman, K., Sarwat, S., Abbas, C. A., Ramirez, M. A., Grines, C. L., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.043655 · Cited by 3
Mining of adverse event signals associated with inclisiran: a post-marketing analysis based on FAERS
Shi, X., Qiao, Y., Yang, Y., Wang, N., Zhang, Y., Shi, S., Shen, G., & Jia, X. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2409707 · Cited by 3
Wilson, P. M., Elvey, R., Mathieson, A., Bower, P., Gibson, M., Vell, T., & Dixon, S. (2025) · BMJ Open · doi:10.1136/bmjopen-2023-083441 · Cited by 4
Looking for lipoprotein(a) in youngsters: a call to action
Bilato, C., Zuin, M., & Rigatelli, G. (2025) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001717 · Cited by 3
Therapeutic Management of LDL-C: Efficacy and Economic Impact Assessment
Elshafeey, A. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12050196 · Cited by 3
Maligłówka, M., Dec, A., Bułdak, Ł., & Okopień, B. (2025) · Pharmaceuticals · doi:10.3390/ph18060832 · Cited by 3
Ogunniyi, K. E., Aghasili, C. C., Akinmoju, O. D., Olaiya, V. O., Abib, O. M., Odueke, A., Popoola, H. A., Onyenokwe, V., Onaolapo, D., Usman, A.-A. M., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00762-9 · Cited by 3
Emerging therapies targeting lipoprotein(a): Pharmacologic advances and future directions
Perez, A. D., Simpson, R. J., Komé, A. M., & Lopez, S. T. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103695 · Cited by 3
Homozygous familial hypercholesterolemia and its treatment by inclisiran
Marais, A. D., Blom, D. J., & Raal, F. J. (2020) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2020.1784721 · Cited by 3
Self-citationThe pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs
Ballantyne, C. M., & Catapano, A. L. (2022) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i1.7 · Cited by 3
A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms
Orringer, C. E., Grant, J. K., & Tokgözoğlu, L. S. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01059-x · Cited by 3
Lipidtherapie bei Patienten mit Diabetes mellitus
Parhofer, K. G., Birkenfeld, A. L., Krone, W., Lehrke, M., Marx, N., Merkel, M., Schütt, K. S., Zirlik, A., & Müller‐Wieland, D. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00905-5 · Cited by 3
Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus
Rakočević, J., Dobric, M. R., Vučić, R. M., Furtula, M., Zaletel, I. V., Milutinović, K., Ilijevski, A., Labudović‐Borović, M., Tomasevic, M. V., & Bajčetić, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24066012 · Cited by 5
Small molecule inhibitors of PCSK9. SAR investigations of head and amine groups
Aspnes, G. E., Coffey, S. B., Darout, E., Dechert‐Schmitt, A. R., Dullea, R., Kamlet, A. S., Limberakis, C., Londregan, A. T., McClure, K. F., Menhaji‐Klotz, E., et al. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129394 · Cited by 3
PCSK9 siRNA INHIBITOR INCLISIRAN AS A TREATMENT OPTION IN HYPERCHOLESTEROLEMIA: A BRIEF REVIEW
Kılıç, M. E. (2023) · TURKISH MEDICAL STUDENT JOURNAL · doi:10.4274/tmsj.galenos.2023.2023-5-1 · Cited by 3
Idiosyncratic Drug-Induced Liver Injury in a Healthy Patient following PCSK9-Inhibitor Injection
Stüben, B.-O., Hoyer, D. P., Radünz, S., Saner, F. H., Schmidt, H., Baba, H. A., Treckmann, J. W., & Mazilescu, L. (2024) · Case Reports in Hepatology · doi:10.1155/2024/5556907 · Cited by 3
A Facile and Promising Delivery Platform for siRNA to Solid Tumors
Leng, Q., Anand, A., & Mixson, A. J. (2024) · Molecules · doi:10.3390/molecules29235541 · Cited by 3
Huang, Z., Zhang, W., Wang, D.-Z., Zhang, Y., Duan, Y.-B., He, X., Gao, Y.-X., Jia, Z.-N., & Qian, X. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2446407 · Cited by 4
Li, J., Huang, S., Hu, X. X., & Chen, J. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s493912 · Cited by 3
Inclisiran, the billion-dollar drug, to lower LDL cholesterol – is it worth it?
Doggrell, S. A. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1799978 · Cited by 3
A Lipid lover’s Guide to Novel Therapeutics for Lipid and Cardiovascular Risk Reduction
Hritani, R., Hussain, A., Saeed, A., & Agarwala, A. (2021) · Future Cardiology · doi:10.2217/fca-2020-0216 · Cited by 3
Arnesen, K.-E., Phung, A. V., Randsborg, K., Mork, I., Thorwall, M., Langslet, G., Svilaas, A., Wium, C., Ose, L., & Retterstøl, K. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.560958 · Cited by 3
Tissue-Specific Cell Penetrating Peptides for Targeted Delivery of Small Interfering RNAs
Lopuszynski, J. B., Agrawal, V., & Zahid, M. (2022) · Medical Research Archives · doi:10.18103/mra.v10i8.2998 · Cited by 3
Lang, K., Iterson, E. H. V., & Laffin, L. J. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00203-5 · Cited by 3
Personalized medicine in non-communicable diseases: latest advances and future prospects
Drapkina, O. M., & Иванова, А. А. (2021) · Kardiologiia · doi:10.18087/cardio.2021.11.n1233 · Cited by 3
Familial hypercholesterolaemia and emerging therapeutics
Farias, F. I., Kim, S. M., & Shapiro, M. D. (2023) · Heart · doi:10.1136/heartjnl-2022-321917 · Cited by 3
Familial hypercholesterolaemia: New directions on the diagnosis and treatment of an old disease
Rallidis, L. S., & Kosmas, N. (2020) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2020.06.014 · Cited by 3
Pirillo, A., Casula, M., Baragetti, A., & Catapano, A. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00001-7 · Cited by 3
Klose, G., Gouni‐Berthold, I., & März, W. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01524-y · Cited by 2
Lis, P., Lis, A. E., Kaźmierski, W., Jurek, J., Ziomek, M., Kocur, K., Ziobro, A., & Camlet, K. (2024) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.241 · Cited by 3
Allevi, M., Landolfo, M., Giulietti, F., Spannella, F., & Sarzani, R. (2025) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytaf061 · Cited by 2
Small interfering RNA effect on lipoprotein(a): a systematic review
Almaadawy, O., Hesn, M., Elsalamony, Y. A., Abobakr, O. A., Elshimy, A., Abualkhair, K. A., Negm, M. M., Shaban, A. Y., Bene-Alhasan, Y. O., Annie, F., et al. (2025) · The Egyptian Heart Journal · doi:10.1186/s43044-025-00635-1 · Cited by 4
An evaluation of recaticimab for the treatment of hypercholesterolemia
Tang, X. L., Hooper, A. J., & Burnett, J. R. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2508837 · Cited by 2
Korneva, V. A., & Kuznetsova, T. Y. (2025) · Kardiologiia · doi:10.18087/cardio.2025.6.n2950 · Cited by 2
PCSK9 Inhibitor and Potential Decreased Risk of Neoplasms, Especially in Females: A Meta-Analysis
Wei, T., Li, Z., Lin, C., Yang, Y., Tie, C., Cai, X., Lv, F., Yang, W., & Ji, L. (2025) · Pharmaceuticals · doi:10.3390/ph18081095 · Cited by 2
Ahlers, M. J., John, S., Bhatia, H. S., Le, V. T., & Taub, P. R. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101265 · Cited by 4
Modified unlocked nucleic acid (MUNA) mitigates off-target effects of small interfering RNAs
Mori, S., Datta, D., Perkins, L. A., Jung, M., Woods, L. B., Eaton, A., Qin, J., Racie, T., Kim, M., Guenther, D. C., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf937 · Cited by 2
Mojahedi, A., Chen, O., Skopicki, H. A., Rahman, T., & Sadeghian, A. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm42784 · Cited by 3
Kim, H. (2025) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2025.7.e17 · Cited by 2
Inclisiran-Induced Fixed Drug Eruption in a Patient With Refractory Hypercholesterolemia
Khan, J. A., & Shahab, S. (2025) · Cureus · doi:10.7759/cureus.98687 · Cited by 2
Lipoprotein(a) and Aortic Valve Stenosis: From Pathophysiology to Emerging Pharmacological Agents
Agnello, F. G., Laterra, G., Scalia, L., Mauro, M. S., Strazzieri, O., Reddavid, C., Ingala, S., Guarino, S., Barbera, C., Russo, M. D., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm15010274 · Cited by 2
2′-Ribose-modified nucleotides: A strategy for reducing off-target effects of oligonucleotide drugs
Zhang, H., Liu, Y., Ma, J., Huang, H., Zhang, W., Xiu, D., Ma, T., Zhang, M., Yu, F., & Song, G. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102835 · Cited by 3
Xiao, Q., Wang, M., Wang, S., Wang, L., & Ding, H. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-025-07647-0 · Cited by 2
Inclisiran in Chronic Kidney Disease Patients: A Real-World Experience
Strologo, A. D., Franculli, A., Saporito, P., Miani, N., Bellasi, A., Lido, P., Lullo, L. D., Ronco, C., & Peverini, P. (2026) · Cardiorenal Medicine · doi:10.1159/000549898 · Cited by 3
Li, X., Elebring, M., Heijer, M., Vega, R. B., Rudvik, A., Singh, N. K., Simmonds, R., Pelay-Gimeno, M., Reinen, J., Vedin, C., et al. (2026) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70162 · Cited by 2
Zhang, X., Ren, Q., Guo, X., Chen, Y., Sun, S., Wang, M., Ren, X., Liu, C., & Mengqi, Z. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121473 · Cited by 2
Molecular and Genetic Aspects of Lipid Metabolism Disorders and Potential Targets for Gene Therapy
Akhmetzyanova, E. R., Викторовна, Т. А., Gallyamov, D. R., Rizvanov, A. A., & Mukhamedshina, Y. O. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.2.195 · Cited by 3
Mauriello, A., Falco, A. D., Correra, A., D’Andrea, A., Giallauria, F., Giordano, A., & Russo, V. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01414-2 · Cited by 2
Feldman, D. I., Wu, K. C., Hays, A. G., Marvel, F. A., Martin, S. S., Blumenthal, R. S., & Sharma, G. V. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100181 · Cited by 2
Gene Silencing Therapeutics in Cardiology: A Review Article
Jay, P. Y., Maier, M. A., Saltonstall, L., Duarte, L., Antonino, I., & Vest, J. (2021) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20200306 · Cited by 2
Mesyl Phosphoramidate Oligonucleotides: A New Promising Type of Antisense Agents
Stetsenko, D. A. (2023) · Springer eBooks · doi:10.1007/978-981-19-9776-1_19 · Cited by 2
Hypercholesterinämie und kardiovaskuläres Risiko
Sinning, D., & Landmesser, U. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1932-6448 · Cited by 2
Gordon, S., Layton, A., Fawcett, S. A., & Ross, K. (2024) · Dermatology Reports · doi:10.4081/dr.2024.9902 · Cited by 2
Metadata
- Authors
- Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., & Kastelein, J. J. P.
- Affiliations
- University of the Witwatersrand (ZA)
- Medpace (United States) (US)
- From the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa (F.J.R.); the Medicines Company, Zurich, Switzerland (D.K.); the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College, London (K.K.R.); Medpace Reference Laboratories, Cincinnati (T.T.); Deutsches Herzzentrum München, Technische Universität München, and German Center for Cardiovascular Research, Munich Heart Alliance, Munich (W.K.), and the...
- Mayo Clinic (US)
- St. Michael's Hospital (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-04-16
- Volume
- 382
- Issue
- 16
- Pages
- 1520-1530
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3011005820
- Semantic Scholar
- cd7f15bcb062953bf710c34645a08f7b4818c4d9
- Cited by
- 818
- References
- 52
- Citations by year
- 2026: 88 · 2025: 126 · 2024: 142 · 2023: 154 · 2022: 140 · 2021: 111 · 2020: 56
- FWCI
- 105.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- inclisiran, heterozygous familial hypercholesterolemia, PCSK9 inhibition, siRNA, LDL cholesterol lowering, atherosclerotic cardiovascular disease prevention, hypercholesterolemia treatment, lipid-lowering therapy, PCSK9 monoclonal antibodies
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Anticholesteremic Agents, Double-Blind Method, Female, Humans, Hyperlipoproteinemia Type II, Injections, Subcutaneous, Cholesterol, LDL, Male, Middle Aged, Treatment Outcome, RNA, Small Interfering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
